Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2651-2660 Newer>

The Motley Fool January 25, 2006 Stephen D. Simpson	Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out.
The Motley Fool January 24, 2006 Richard Gibbons	A Seductively Cheap Growth Stock Clinical development services provider SFBC has some significant barriers against competition. But if the company's so great, why is its stock so cheap?
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
BusinessWeek January 30, 2006 John Carey	How Safe Are Diet Supplements? FDA regulation for diet supplements is weak, so private watchdogs are stepping in.
BusinessWeek January 30, 2006 Howard Gleckman	Plan A: Hook Them With Part D Humana's low-cost Medicare drug plan is a way to lure seniors into its managed care.
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
The Motley Fool January 23, 2006 Tim Beyers	Scrushy's Dirty PR Campaign The former HealthSouth CEO is accused of paying for positive ink during his trial. Here's a reminder to every investor that it is important to trust the news, but then verify what you read.
BusinessWeek January 30, 2006 Ellen Hoffman	Smart Gadgets For Seniors New high-tech devices that keep tabs on vital signs, level of activity, medications, and more can help the elderly maintain their independence.
The Motley Fool January 20, 2006 Rich Duprey	Generics Give Originators Heartburn Eisai, the Japanese manufacturer of an acid reflux remedy, sees a generic maker win FDA approval. What does this mean for investors?
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
<Older 2651-2660 Newer> Return to current articles.